Results 41 to 50 of about 433,882 (351)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
New England Journal of Medicine, 2017 To the Editor: Sandborn et al. (May 4 issue)1 raise two important issues that deserve attention. First, when patients with moderate-to-severe ulcerative colitis show no improvement in response to treatment with mesalamine or a dosage of glucocorticoids ...
W. Sandborn +17 more
semanticscholar +2 more sources
Current Research in Pharmacology and Drug Discovery, 2022 The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules.
Pascal Juillerat +5 more
doaj
Analysis of Clinical and Histopathological Findings in Microscopic Colitis
Türk Patoloji Dergisi, 2022 Objective: Microscopic colitis is a chronic inflammatory disorder characterized by a triad of chronic diarrhea, endoscopy without significant abnormality, and distinct histopathological features. Histopathologically, microscopic colitis is divided into 3
Gozde TOPEL +4 more
doaj +1 more source
Canadian Journal of Gastroenterology, 2009 The issue of dysplasia within the setting of chronic colitis is rapidly evolving, and more aggressive endoscopic management and surveillance is clearly being suggested in selected cases (1–3). With the advent of more effective therapies such as tumour necrosis factor inhibitors, it has been suggested that some patients are likely to be managed with ...
Robert Enns, Brian Bressler
openaire +3 more sources
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
New England Journal of Medicine, 2013 BACKGROUND Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients ...
B. Feagan +15 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.TGF‐β has a complex role in cancer, exhibiting both tumor‐suppressive and tumor‐promoting properties. Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐
Theresia Mair +17 more
wiley +1 more source
Gut Microbes, 2021 Human milk oligosaccharides (HMOs) and milk fat globule membrane (MFGM) are highly abundant in breast milk, and have been shown to exhibit potent immunomodulatory effects.
Cong Liu +9 more
doaj +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Theranostics, 2020 Background: Gut microbiota, which plays a crucial role in inflammatory bowel diseases (IBD), might have therapeutic benefits for ulcerative colitis or Crohn's disease. Targeting gut microbiota represents a new treatment strategy for IBD patients.
Jiawei Wu +9 more
semanticscholar +1 more source
Gut alterations in a chronic kidney disease rat model with diet‐induced vascular calcification
FEBS Open Bio, EarlyView.Chronic kidney disease (CKD) patients often suffer from intestinal and/or mineral and bone disorders. Using a rat model, we showed that uremic vascular calcification is associated with gut barrier alterations (decreased gut mucus production and Nlrp6 gene expression, increased gut inflammation), and plasma retention of gut‐origin uremic toxins (indoxyl
Piotr Bartochowski +13 more
wiley +1 more source